Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
D. Singh (Manchester, United Kingdom), M. Govoni (Parma, Italy), M. Bassi (Parma, Italy), K. Beeh (Wesbaden, Germany), B. Colgan (Belfast, United Kingdom), O. Kornmann (Frankfurt, Germany), B. Laeker (London, United Kingdom), H. Watz (Grosshansdorf, Germany), G. Lucci (Parma, Italy), S. Geraci (Parma, Italy), E. Calabro Rocco (Parma, Italy), A. Emirova (Bois Colombes, France), M. Nandeuil (Bois Colombes, France)
Source: International Congress 2019 – Advances in COPD pharmacology
Session: Advances in COPD pharmacology
Session type: Poster Discussion
Number: 2044
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Singh (Manchester, United Kingdom), M. Govoni (Parma, Italy), M. Bassi (Parma, Italy), K. Beeh (Wesbaden, Germany), B. Colgan (Belfast, United Kingdom), O. Kornmann (Frankfurt, Germany), B. Laeker (London, United Kingdom), H. Watz (Grosshansdorf, Germany), G. Lucci (Parma, Italy), S. Geraci (Parma, Italy), E. Calabro Rocco (Parma, Italy), A. Emirova (Bois Colombes, France), M. Nandeuil (Bois Colombes, France). Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients. 2044
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002